VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Necchi A, Basile G, Gibb EA, Raggi D, et al. BJU Int 2023 Oct 6. doi: 10.1111/bju.16191.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Necchi A, Basile G, Gibb EA, Raggi D, et al. VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. BJU Int 2023 Oct 6. doi: 10.1111/bju.16191.
PMID: 37803523